| 1 |
NCT00500487 |
Completed |
Therapeutic Schools: Affect Management and HIV Prevention |
|
- Behavioral: Affect Management
- Behavioral: HIV Prevention Skills
- Behavioral: General Health Promotion
|
Interventional
|
Phase 1 |
- Rhode Island Hospital
- University of Chicago
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Adolescent-reported condom use
|
420 |
All |
13 Years to 18 Years (Child, Adult) |
NCT00500487 |
R01MH066641 |
|
April 2003 |
June 2010 |
June 2010 |
July 12, 2007 |
January 12, 2015 |
|
- Rhode Island Hospital
Providence, Rhode Island, United States
|
|
| 2 |
NCT00502944 |
Completed
Has Results |
Two Approaches to Routine HIV Testing in a Hospital Emergency Department |
|
- Behavioral: Counselor-based HIV screening
- Behavioral: Emergency staff member-based HIV screening
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Linkage to Care of Newly Diagnosed HIV Infected Participants
- Overall Rapid HIV Testing Rate
|
4855 |
All |
18 Years and older (Adult, Older Adult) |
NCT00502944 |
R01MH073445
DAHBR 9A-ASPQ |
|
February 2007 |
July 2008 |
July 2008 |
July 18, 2007 |
July 19, 2012 |
July 13, 2012 |
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
|
| 3 |
NCT00490152 |
Completed |
Microbicides Acceptability Among Sexually Active Young Women |
|
- Behavioral: Automated diary system
|
Observational
|
|
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Microbicide use adherence as measured by a computerized phone diary
- Microbicide use adherence as measured by e-mail messages
- Microbicide use adherence as measured by in-depth interviews via teleconference
- (and 6 more...)
|
59 |
Female |
18 Years to 24 Years (Adult) |
NCT00490152 |
ATN 062 |
|
August 2007 |
November 2009 |
November 2009 |
June 22, 2007 |
February 28, 2017 |
|
- University of South Florida College of Medicine
Tampa, Florida, United States - University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States - University Pediatric Hospital
San Juan, Puerto Rico
|
|
| 4 |
NCT00505401 |
Completed |
Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS |
|
- Biological: recombinant HIV-1 Tat protein
|
Interventional
|
Phase 1 |
- Istituto Superiore di Sanità
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Assessment of product safety included clinical monitoring of volunteers for local and systemic adverse reactions during the course of the trial and monitoring of haematological, biochemical, virological and immunological parameters
- To qualify Tat protein as immunogenic, volunteers were monitored for anti-Tat specific antibodies (IgM, IgG, IgA), anti-Tat proliferative response and in vitro γIFN and IL-4 production by PBMC before vaccination and in response to Tat vaccine.
|
27 |
All |
18 Years to 50 Years (Adult) |
NCT00505401 |
ISST-001 |
ISST-001 |
December 2003 |
|
November 2007 |
July 23, 2007 |
March 1, 2011 |
|
- San Raffaele Hospital
Milan, Italy - Hospital Spallanzani
Rome, Italy - San Gallicano Hospital
Rome, Italy - University of Rome "La Sapienza"
Rome, Italy
|
|
| 5 |
NCT00496691 |
Completed |
HIV Prevention for Youth With Severe Mental Illness |
|
- Behavioral: Family-based HIV prevention program
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- condom use; sexual delay
- parent-adolescent sexual communication
- condom use attitudes
|
718 |
All |
13 Years to 18 Years (Child, Adult) |
NCT00496691 |
R01-MH63008-5
R01MH063008 |
|
April 2002 |
December 2010 |
December 2010 |
July 4, 2007 |
May 20, 2016 |
|
- Rhode Island Hospital
Providence, Rhode Island, United States
|
|
| 6 |
NCT00494273 |
Completed |
HIV Prevention in Haitian American Adolescents |
|
- Behavioral: Cognitive Behavioral and Standard Care with Healthy Living
|
Interventional
|
Phase 1
Phase 2 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single
- Primary Purpose: Prevention
|
- The BART Condition will reduce HIV transmission risk behavior over time more than the SC. Assessments will be completed prior, after, 4 , 8 and 12 months after the intervention. Measure examples are
- Sexual and Condom Attitudes
- Self-Efficacy Scale
- (and 10 more...)
|
320 |
All |
14 Years to 17 Years (Child) |
NCT00494273 |
R01HD038458 |
|
December 2002 |
December 2006 |
December 2006 |
June 29, 2007 |
October 29, 2014 |
|
- Center for Haitian Studies
Miami, Florida, United States
|
|
| 7 |
NCT00503308 |
Completed
Has Results |
HIV Testing Strategies in the Perinatal Setting |
- HIV Infections
- Pregnancy Related
|
- Procedure: Abbreviated HIV test counseling
|
Interventional
|
Not Applicable |
- University of California, San Francisco
- Pfizer
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Health Services Research
|
- Satisfaction With HIV Testing Experience (O'Connor Decisional Conflict Scale)
|
281 |
Female |
16 Years and older (Child, Adult, Older Adult) |
NCT00503308 |
2004-0319 |
|
October 2006 |
September 2007 |
February 2008 |
July 18, 2007 |
May 22, 2015 |
July 1, 2011 |
- UCSF, San Francisco General Hospital
San Francisco, California, United States
|
|
| 8 |
NCT00490074 |
Completed |
Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers |
|
- Biological: DNA-C
- Biological: NYVAC-C
|
Interventional
|
Phase 1
Phase 2 |
- French National Agency for Research on AIDS and Viral Hepatitis
- EuroVacc Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Immunogenicity parameter: presence of CD8/CD4+ T cell responses defined according to internationally agreed criteria for evaluation of IFNgamma ELISPOT assays, in response to env plus at least one of the gag, pol, nef peptide pools
- Safety parameter: grade 3 or above local adverse event, grade 3 or above systemic adverse event, grade 3 or above other clinical or laboratory adverse event,any event attributable to vaccine leading to discontinuation of the immunisation regimen.
- Cellular responses: CD8/CD4+ T cell mean IFNgamma Spot Forming Units (SFU) per million cells across the peptide pools
- (and 6 more...)
|
147 |
All |
18 Years to 55 Years (Adult) |
NCT00490074 |
2006-006141-13
EV03/ANRSVAC20 |
EV03/ANRSVAC20 |
July 2007 |
December 2008 |
October 2009 |
June 22, 2007 |
November 26, 2009 |
|
- Hôpital Henri Mondor
Créteil, France - Centre Hospitalier Universitaire Vaudois CHUV
Lausanne, Switzerland
|
|
| 9 |
NCT00498056 |
Withdrawn |
Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa |
|
- Biological: VRC-HIVDNA016-00-VP
- Biological: VRC-HIVADV014-00-VP
- Biological: VRC-HIVDNA016-00-VP placebo
- Biological: VRC-HIVADV014-00-VP placebo
|
Interventional
|
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Centers for Disease Control and Prevention
- HIV Vaccine Trials Network
- (and 3 more...)
|
NIH / U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- Acquisition of HIV infection, reduction in viral load in those who become infected, and adverse events (AEs)
- Seroconversion with HIV RNA or HIV DNA detection, average of two viral load measurements, and AEs graded on the DAIDS AE Grading Table
|
0 |
All |
18 Years to 45 Years (Adult) |
NCT00498056 |
PAVE 100
10500 |
|
|
|
|
July 9, 2007 |
March 27, 2012 |
|
|
|
| 10 |
NCT00504452 |
Terminated |
Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the safety and tolerability of KP-1461 for 124 days in treatment-experienced, HIV-1-infected subjects.
- To evaluate the antiviral activity (eg., CD4 count, HIV RNA count) of KP-1461 for 124 days in treatment-experienced, HIV-1-infected subjects.
|
27 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00504452 |
KP-1461-201 |
|
July 2007 |
September 2008 |
June 2009 |
July 20, 2007 |
November 7, 2011 |
|
- Health for Life Clinic
Little Rock, Arkansas, United States - Living Hope Clinical Foundation
Long Beach, California, United States - Light Source Medical/U. of Southern California
Los Angeles, California, United States - (and 28 more...)
|
|
| 11 |
NCT00496782 |
Terminated
Has Results |
Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay |
|
- Drug: maraviroc
- Procedure: Trofile Assay and HIV RNA quantification assay
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Change From Baseline in Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) With R5 & Non-R5 Tropism Results From the Trofile(tm) Assay
- Subjects Achieving HIV-1 RNA <400 Copies/mL
- Subjects Achieving HIV-1 RNA <50 Copies/mL
- (and 11 more...)
|
16 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT00496782 |
A4001060 |
|
July 2007 |
October 2008 |
October 2008 |
July 4, 2007 |
November 19, 2010 |
March 19, 2010 |
- Pfizer Investigational Site
Miami, Florida, United States - Pfizer Investigational Site
Chicago, Illinois, United States - Pfizer Investigational Site
Topeka, Kansas, United States - (and 7 more...)
|
|
| 12 |
NCT00491556 |
Completed
Has Results |
Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r) |
|
- Procedure: Early Initiation of Highly Active Anti-Retroviral Therapy
- Procedure: Standard Care
|
Interventional
|
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Difference in CD4+ T Cell Percentage Between Week 0 and Week 48
- Difference in CD4+ T Cell Percentage Between Week 48 and Week 152
- Difference in CD4+ T Cell Count Between Week 0 and Week 48
- (and 49 more...)
|
102 |
All |
18 Years to 24 Years (Adult) |
NCT00491556 |
ATN 061 |
|
October 2007 |
June 2013 |
June 2013 |
June 26, 2007 |
March 29, 2017 |
June 24, 2016 |
- Children's Hopsital of Los Angeles
Los Angeles, California, United States - University of Southern California - IMPAACT Site
Los Angeles, California, United States - University of California at San Francisco
San Francisco, California, United States - (and 20 more...)
|
|
| 13 |
NCT00489385 |
Completed |
An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals |
|
- Drug: Albinterferon
- Drug: Ribavirin
- Drug: Albuferon
|
Interventional
|
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of two doses of Albinterferon alpha 2b with ribavirin.
- Histologic, virologic responses to Albinterferon alpha 2b and ribavirin
|
41 |
All |
18 Years and older (Adult, Older Adult) |
NCT00489385 |
070001
07-I-0001 |
|
June 18, 2007 |
March 15, 2011 |
March 15, 2011 |
June 21, 2007 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 14 |
NCT00497081 |
Completed
Has Results |
Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors |
- Substance Abuse
- HIV Infections
|
- Drug: mirtazapine
- Drug: placebo
|
Interventional
|
Phase 2 |
- San Francisco Department of Public Health
- National Institute on Drug Abuse (NIDA)
- Public Health Foundation Enterprises, Inc.
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Number of Positive Methamphetamine Urine Tests, Comparing Baseline (Week 0) to Final Visit (Week 12).
- Proportion of Days With Recorded Pill Bottle Opening, as Determined by MEMS.
- Frequency of Adverse Events Reported
|
60 |
Male |
18 Years to 60 Years (Adult) |
NCT00497081 |
1R01DA022155-01
R01DA022155
DPMC |
|
May 2007 |
March 2010 |
March 2010 |
July 6, 2007 |
January 5, 2015 |
October 20, 2014 |
- San Francisco Department of Public Health, Substance Use Research Unit
San Francisco, California, United States
|
|
| 15 |
NCT00497055 |
Completed
Has Results |
Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals |
- Substance Abuse
- HIV Infections
|
- Drug: Aripiprazole
- Drug: Placebo
|
Interventional
|
Phase 2 |
- San Francisco Department of Public Health
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To Test the Hypothesis That Aripiprazole 20 mg Daily Will Reduce Methamphetamine Use Significantly More Than Placebo Among Methamphetamine-dependent Individuals.
- To Measure the Acceptability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, by Determining (Via Electronic Pill Caps [MEMS or Medication Event Monitoring System]) Medication Adherence to Aripiprazole and Placebo.
- To Measure the Safety and Tolerability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, as Determined by the Number of Adverse Clinical Events in the Aripiprazole and Placebo Arms.
|
90 |
All |
18 Years to 60 Years (Adult) |
NCT00497055 |
1R01DA022190-01
1R01DA023387-01
DPMC |
|
March 2009 |
March 2012 |
March 2012 |
July 6, 2007 |
March 24, 2014 |
March 24, 2014 |
- San Francisco Department of Public Health, AIDS Office
San Francisco, California, United States
|
|
| 16 |
NCT00503633 |
Completed |
Biomarkers of Insomnia and Fatigue in HIV/AIDS (Symptoms and Genetics Study) |
|
|
Observational
|
|
- University of California, San Francisco
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
350 |
All |
18 Years and older (Adult, Older Adult) |
NCT00503633 |
SAG |
SAG |
March 2005 |
May 2009 |
May 2009 |
July 19, 2007 |
June 23, 2010 |
|
- University of California, San Francisco
San Francisco, California, United States
|
|
| 17 |
NCT00495651 |
Completed |
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) |
- HIV Infections
- Tuberculosis
|
- Drug: Antiretroviral medications
- Drug: Antiretroviral medications+Isoniazid prophylaxis
|
Interventional
|
Phase 3 |
- French National Agency for Research on AIDS and Viral Hepatitis
- Gilead Sciences
- Merck Sharp & Dohme Corp.
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Death (all-cause), or severe HIV-related disease (AIDS-defining diseases, non-AIDS-defining malignancies, and non-AIDS-defining invasive bacterial diseases)
- prevalence of HIV resistance (ANRS12253 associated study)
- Grade 3 or 4 clinical events (including cardiovascular, renal and bone disease) and laboratory test results, as defined by the ANRS classification system of drug-related adverse events
- (and 9 more...)
|
2073 |
All |
18 Years and older (Adult, Older Adult) |
NCT00495651 |
ANRS 12136 TEMPRANO |
TEMPRANO |
March 2008 |
January 2015 |
January 2015 |
July 3, 2007 |
June 3, 2015 |
|
- Centre de prise en charge de personnes vivant avec le VIH la pierre angulaire
Abidjan, Côte D'Ivoire - Centre de Prise en Charge et de Formation ACONDA
Abidjan, Côte D'Ivoire - Centre de Suivi des donneurs de sang, Centre National de Transfusion Sanguine
Abidjan, Côte D'Ivoire - (and 6 more...)
|
|
| 18 |
NCT00503230 |
Completed |
Reducing Ethnic Health Disparities: Motivating HIV+ Latinos to Quit Smoking |
- Tobacco Dependence
- HIV Infections
|
- Behavioral: Standard Care Intervention (SCI)
- Behavioral: Culturally Tailored Intervention (CTI)
|
Interventional
|
Phase 3 |
- Butler Hospital
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
400 |
All |
18 Years and older (Adult, Older Adult) |
NCT00503230 |
R01DA018079 |
AURORA |
October 2005 |
July 2011 |
July 2011 |
July 18, 2007 |
May 3, 2013 |
|
- Lowell Community Health Center
Lowell, Massachusetts, United States - Greater New Bedford Community Center
New Bedford, Massachusetts, United States - Dimock Community Health Center
Roxbury, Massachusetts, United States - (and 5 more...)
|
|
| 19 |
NCT00494936 |
Completed |
Effects of HIV and Hepatitis C Virus on the Brain |
- HIV Infections
- Hepatitis C
|
|
Observational
|
|
- Icahn School of Medicine at Mount Sinai
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
78 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00494936 |
GCO 03-0908
K23MH071181
DAHBR 9A-ASNM |
|
May 2006 |
July 2009 |
July 2009 |
July 2, 2007 |
May 25, 2015 |
|
- Mount Sinai School of Medicine
New York, New York, United States
|
|
| 20 |
NCT00489528 |
Completed |
Growth Hormone in the Treatment of HIV-Associated Wasting |
- HIV Infections
- HIV Wasting Syndrome
|
- Drug: Somatropin; Recombinant human growth hormone (r hGH)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- To confirm the clinical efficacy of Serostim compared with placebo, based on an endpoint of exercise function change.
- To establish an optimal dose of Serostim, based on the endpoint of lean body mass (LBM) change.
|
|
All |
18 Years and older (Adult, Older Adult) |
NCT00489528 |
9037 |
|
July 1997 |
|
March 2002 |
June 21, 2007 |
October 22, 2013 |
|
|
|
| 21 |
NCT00490412 |
Completed |
Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection |
|
- Dietary Supplement: Vitamin D supplement
- Other: Placebo
|
Interventional
|
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- To compare the change in renal tubular reabsorption of phosphate and markers of bone turnover.
- To measure the safety of 50,000 IU dose of vitamin D3
- To measure the relationship of vitamin D plasma concentrations to renal tubular reabsorption of phosphate and markers of bone turnover
- (and 2 more...)
|
207 |
All |
18 Years to 24 Years (Adult) |
NCT00490412 |
ATN 063 |
|
December 2007 |
January 2010 |
January 2010 |
June 22, 2007 |
February 28, 2017 |
|
- Children's Hopsital of Los Angeles
Los Angeles, California, United States - University of California at San Francisco
San Francisco, California, United States - Children's National Medical Center
Washington, District of Columbia, United States - (and 12 more...)
|
|
| 22 |
NCT00499876 |
Completed |
The Effect of Malaria on Disease Progression of HIV/AIDS |
|
- Drug: mefloquine
- Other: placebo
|
Interventional
|
Not Applicable |
- London School of Hygiene and Tropical Medicine
- Noguchi Memorial Institute for Medical Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Measure the effects of antimalarials on CD4 cell count decline and HIV viral load increase in study patients
- Measure the effect of malaria prophylaxis on malaria parasitaemia and haemoglobin levels in study patients
|
197 |
All |
19 Years and older (Adult, Older Adult) |
NCT00499876 |
REG_9
KATH_GMP_1 |
|
October 2007 |
October 2008 |
December 2009 |
July 12, 2007 |
January 26, 2017 |
|
- Komfo Anokye Teaching Hospital
Kumasi, Ghana
|
|
| 23 |
NCT00502827 |
Completed |
Smoking Cessation for HIV/AIDS Patients |
- Human Immunodeficiency Virus
|
- Behavioral: Cell Phone Intervention
- Other: Recommended Standard of Care
|
Interventional
|
Not Applicable |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of participants in the two intervention groups who are abstinent as measured by point prevalence
|
706 |
All |
18 Years and older (Adult, Older Adult) |
NCT00502827 |
2003-0784
NCI-2012-02109 |
|
January 2004 |
April 2015 |
April 2015 |
July 18, 2007 |
February 26, 2016 |
|
- Thomas Street Clinic
Houston, Texas, United States - University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 24 |
NCT00495677 |
Completed
Has Results |
A Phase 2 Study Of PF-00232798 In HIV Positive Patients |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in Log 10-transformed Human Immunodeficiency Virus (HIV) Viral Load at Day 11
- Number of Participants With Time to Rebound of Human Immunodeficiency Virus (HIV) Viral Load
- Maximum Observed Plasma Concentration (Cmax)
- (and 2 more...)
|
43 |
Male |
18 Years to 55 Years (Adult) |
NCT00495677 |
A7691009 |
|
June 2007 |
September 2008 |
September 2008 |
July 3, 2007 |
October 30, 2013 |
October 30, 2013 |
- Pfizer Investigational Site
Frankfurt am Main, Germany - Pfizer Investigational Site
Koeln, Germany
|
|
| 25 |
NCT00503347 |
Completed |
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus |
- Hepatitis C Virus
- Hiv Infections
|
|
Interventional
|
Phase 1 |
- Peregrine Pharmaceuticals
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- • Adverse events • Laboratory evaluations • Human anti-chimeric antibody • Pharmacokinetic analysis
- Blood levels of HCV RNA and HIV RNA (PCR)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT00503347 |
PPHM 0603 |
|
July 2007 |
March 2011 |
June 2011 |
July 18, 2007 |
June 9, 2011 |
|
- Impact Clinical Research
Los Angeles, California, United States - Orange Coast Medical Center
Newport Beach, California, United States - AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States - (and 3 more...)
|
|
| 26 |
NCT00493506 |
Completed |
ProAlgaZyme Novel Algae Infusion: Applications in Immunodeficiency |
- HIV Infections
- Hepatitis B
- Dyslipidemia
|
|
Interventional
|
Not Applicable |
- Health Enhancement Products, Inc.
- University of Yaounde
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- CD4+ T-lymphocytes
- HIV Viral Load
- hsCRP (C-reactive protein)
- (and 4 more...)
|
59 |
All |
19 Years to 45 Years (Adult) |
NCT00493506 |
H-0002-01
087/2006 |
|
May 2006 |
|
September 2006 |
June 28, 2007 |
June 28, 2007 |
|
- Laboratory of Nutrition and Nutritional Biochemistry (LNNB), Department of Biochemistry, University of Yaounde I
Yaounde, Cameroon
|
|
| 27 |
NCT00495326 |
Completed |
Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) |
- Tuberculosis
- Aids
- Hiv Infections
|
- Drug: Nevirapine based therapy
- Drug: Efavirenz based therapy
- Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
|
Interventional
|
Phase 2
Phase 3 |
- French National Agency for Research on AIDS and Viral Hepatitis
- Medecins Sans Frontieres, Netherlands
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Viral load measure (Virological failure will be defined after 2 consecutive measures as : More than 1 log10 increase in plasma HIV-1 RNA concentration for patients with detectable viral load (> 50 copies/mL) at the previous dosage.)
- New or recurrent stage 3 or 4 HIV/AIDS related events
- Deaths after one year
- (and 5 more...)
|
570 |
All |
18 Years and older (Adult, Older Adult) |
NCT00495326 |
ANRS 12146 CARINEMO |
CARINEMO |
December 2007 |
April 2011 |
April 2011 |
July 3, 2007 |
February 15, 2012 |
|
- Health centre of Alto Mae, Chamanculo district
Maputo, Mozambique - Health centre of Josue Macao
Maputo, Mozambique - Health centre of Malavane
Maputo, Mozambique
|
|
| 28 |
NCT00499434 |
Unknown † |
Correlation Between Cytokines and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus |
- Acquired Immune Deficiency Syndrome
- Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
- HIV Infections
|
|
Observational
|
|
- UPECLIN HC FM Botucatu Unesp
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with histopathological hepatic biopsy findings in individuals with HIV/HCV coinfection
- This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with CD4 and HIV viremia values in individuals with HIV/HCV coinfection
|
110 |
All |
18 Years to 60 Years (Adult) |
NCT00499434 |
upeclin/HC/FMB-Unesp-14 |
|
August 2007 |
January 2009 |
February 2010 |
July 11, 2007 |
December 4, 2009 |
|
- SAE e Hospital Dia de Aids
Botucatu, Sao Paulo, Brazil
|
|
| 29 |
NCT00499187 |
Completed |
Fanconi Syndrome Due to ARVs in HIV-Infected Persons |
- HIV Infections
- Fanconi Syndrome
- Kidney Disease
- Renal Impairment
|
|
Observational
|
|
|
Industry |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Time to TDF discontinuation after diagnosis of Fanconi syndrome
- Time to confirmed resolution of Fanconi syndrome
|
56 |
All |
18 Years and older (Adult, Older Adult) |
NCT00499187 |
GS-US-104-0353 |
|
September 2007 |
March 2011 |
March 2011 |
July 11, 2007 |
March 17, 2014 |
|
- Los Angeles, California, United States
- Denver, Colorado, United States
- Miami, Florida, United States
- (and 10 more...)
|
|
| 30 |
NCT00491335 |
Completed |
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers |
- HIV Infections
- AIDS
- Lung Cancer
- (and 2 more...)
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
|
All |
17 Years and older (Child, Adult, Older Adult) |
NCT00491335 |
999907173
07-C-N173 |
|
June 18, 2007 |
|
February 16, 2010 |
June 26, 2007 |
July 2, 2017 |
|
- Johns Hopkins University
Baltimore, Maryland, United States
|
|
Create an RSS feed from your search for:
Download the search results for: